Plasma PK of verinurad in the presence of febuxostat 40 or 80 mg (geometric mean (95% CIs)) (PK population)
| Febuxostat (mg) | Verinurad (mg) | Patient, n | Cmax (ng/mL) | AUC0-24 (ng·h/mL) | Tmax (h) | t1/2 (h)* | fe0-24 (%) |
| 40 | 2.5 | 12 | 3.45 (2.63 to 4.52) | 28.0 (21.2 to 36.9) | 3.50 (1.50 to 8.00) | 13.0 (8.89 to 19.1) | 0.661 (0.437 to 1.00) |
| 5 | 12 | 7.20 (5.55 to 9.34) | 62.2 (47.8 to 80.8) | 3.50 (2.00 to 6.00) | 13.2 (8.11 to 21.4) | 0.657 (0.444 to 0.970) | |
| 10 | 24 | 15.5 (12.9 to 18.6) | 123 (104 to 146) | 3.00 (1.50 to 10.0) | 8.26 (6.71 to 10.2) | 0.810 (0.622 to 1.05) | |
| 15 | 23 | 21.2 (18.0 to 25.1) | 186 (164 to 212) | 3.00 (1.50 to 8.00) | 10.6 (8.41 to 13.3) | 0.692 (0.561 to 0.853) | |
| 20 | 11 | 26.1 (20.1 to 33.9) | 216 (173 to 270) | 3.00 (1.50 to 6.00) | 11.6 (7.17 to 18.8) | 0.717 (0.542 to 0.949) | |
| 80 | 2.5 | 12 | 3.37 (2.42 to 4.68) | 27.4 (19.7 to 38.1) | 2.50 (1.00 to 10.0) | 12.5 (8.18 to 19.2) | 0.622 (0.347 to 1.11) |
| 5 | 12 | 7.54 (5.69 to 9.99) | 57.6†(46.8 to 70.9) | 4.00 (1.50 to 12.0) | 11.3† (7.09 to 18.1) | 0.640 (0.392 to 1.05) | |
| 10 | 13 | 16.1 (12.6 to 20.6) | 138 (106 to 179) | 3.00 (1.00 to 12.0) | 9.64‡ (6.77 to 13.7) | 1.03 (0.710 to 1.49) | |
| 15 | 11 | 20.4 (15.8 to 26.2) | 225 (182 to 278) | 4.00 (2.00 to 6.00) | 10.8 (8.17 to 14.3) | 0.816 (0.493 to 1.35) |
Tmax values are presented as median (range).
*Terminal t1/2 values were calculated from a period of less than twofold of the calculated t1/2 value in more than half the subjects.
†n=11; AUC0-24, t1/2 in one subject were unreportable due to indeterminable terminal half-life.
‡n=12; t1/2 in one subject was unreportable due to indeterminable terminal half-life.
AUC0-24, area under the concentration-time curve from time 0 up to 24 hours postdose; Cmax, maximum observed concentration; t1/2, plasma terminal half-life; Tmax, time of maximum observed plasma concentration.